癌症成人对COVID-19疫苗的全面体液和细胞免疫反应
SerOzNET前瞻性研究纳入395例既往未接种的实体瘤或血液系统恶性肿瘤成人,接种最多五剂COVID-19疫苗。第三剂后总体中和抗体阳性率84%,实体瘤96% vs 血液肿瘤64%(p<0.001);血液肿瘤患者需超过三剂才产生中和抗体,但许多有T细胞反应。严重不良事件罕见,COVID-19感染29%,无死亡。
要点
- 第三剂后中和抗体阳性率:实体瘤96% vs 血液肿瘤64%(p<0.001)。
- 血液肿瘤和抗B细胞治疗是无应答的危险因素。
- 部分血液肿瘤患者第四或第五剂后才首次血清转阳。
核心结论
- COVID-19疫苗接种在实体瘤和血液肿瘤患者中引发B细胞和T细胞反应,安全性可接受。
- 相当比例的血液肿瘤患者需要超过3剂才产生中和抗体,许多表现出T细胞反应,可能是免疫保护的替代途径。
研究设计与样本
- SerOzNET前瞻性研究,纳入既往未接种的实体瘤和血液系统恶性肿瘤成人,接受最多五剂COVID-19疫苗。
- 抗体反应通过活病毒中和试验(中和抗体阳性滴度≥1:20,研究主要终点)和商业检测测量;T细胞反应通过细胞珠阵列测量,阳性定义为对Spike抗原的干扰素γ(IFN-γ)≥10 pg/mL。
- 患者和医生报告的不良事件为次要终点。
主要发现
- 395例成人入组,中位年龄58岁(范围20-85),60%为女性,35%为血液系统恶性肿瘤,2/395(0.5%)基线核衣壳抗体阳性提示既往SARS-CoV-2暴露。
- 初始两剂 course 接种mRNA疫苗(BNT162b2=347;mRNA-1273=1)或病毒载体疫苗(ChadOx1-S=43),外加最多三剂额外剂量。
- 第三剂后中和抗体反应总体84%;实体瘤96% vs 血液肿瘤64%(p<0.001)。
- 无应答的危险因素为血液系统肿瘤和抗B细胞治疗;部分血液肿瘤患者在第四或第五剂后首次血清转阳。
- 许多缺乏中和抗体反应的血液肿瘤患者可见IFN-γ反应;严重不良事件罕见;COVID-19感染发生于29%,无死亡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic has significantly impacted people with cancer. Initial vaccine studies excluded patients with malignancy. Immunocompromised individuals remain vulnerable to SARS-CoV-2, necessitating detailed understanding of vaccine response. The epidemiology of COVID-19 in Australia offered unique opportunities to study cancer populations with minimal community exposure to SARS-CoV-2. METHODS: SerOzNET prospectively examined previously unvaccinated patients with solid and haematological malignancies receiving up to five COVID-19 vaccine doses. Antibody response was measured by live virus neutralisation assay (neutralising antibody (NAb); positive titre ≥1:20; study primary endpoint) and commercial assay. T cell response was measured by cytometric bead array; positive defined as interferon gamma (IFN-γ) ≥10 pg/mL in response to Spike antigen. Patient and physician-reported adverse events were secondary endpoints. OUTCOMES: 395 adults were enrolled prior to receiving mRNA vaccine (BNT162b2 = 347; mRNA-1273 = 1) or viral vector vaccine (ChadOx1-S = 43) for initial two-dose course, plus up to three additional doses. Median age was 58 years (range: 20-85); 60 % were female; 35 % had haematological malignancy, 2/395 (0.5 %) had baseline positive nucleocapsid antibody indicating prior SARS-CoV-2 exposure. NAb response post dose three was demonstrated in 84 % overall; 96 % of patients with solid cancers and 64 % with haematological cancer (p < 0·001). Risk factors for non-response were haematological cancer and anti B-cell therapies. Some patients with haematological cancer seroconverted for the first time after the fourth or fifth dose. IFN-γ response was seen in many patients with haematological cancer who lacked NAb response. Serious adverse events were rare. COVID-19 infection occurred in 29 % with no deaths. INTERPRETATION: COVID-19 vaccination elicits B and T cell responses in patients with solid and haematological cancers, with an acceptable safety profile. A significant proportion of haematological cancer patients require >3 doses to elicit NAb, with many demonstrating T cell response, which may be an alternative pathway of immune protection.
引用
- Body A, Lal L, Srihari S, et al. Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer. Vaccine. 2024. PMID: 39648104. doi:10.1016/j.vaccine.2024.126547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。